Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, Tolerability, and PK/PD of BMS-963272 in Obese Healthy Adults
NCT04116632Phase 1Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Sep 2019
- Primary completion
- Feb 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of BMS-963272 in obesity and Nonalcoholic steatohepatitis (NASH) (3 arms), sponsored by Bristol Myers Squibb. Primary endpoints: Maximum observed plasma concentration of BMS-963272 at Day 14, Time of maximum observed concentration of BMS-963272 at Day 14 and 10 more. Started Sep 2019; status: completed.
02
Drugs
BMS-963272
03
Conditions
obesityNonalcoholic steatohepatitis (NASH)
Beyond the preview
Go deeper on NCT04116632.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04116632.